DANIEL JAVITT (Cochair), New York University
CHI-MING LEE (Cochair), AstraZeneca Pharmaceuticals
HUDA AKIL, University of Michigan
MARK BEAR, Massachusetts Institute of Technology
JOHN DUNLOP, Pfizer
RICHARD FRANK, GE Healthcare, Inc.
WALTER KOROSHETZ, National Institute of Neurological Disorders and Stroke
MENELAS PANGALOS, AstraZeneca Pharmaceuticals
WILLIAM POTTER, Foundation for NIH Neuroscience Biomarker Steering Committee
RAE SILVER, Columbia University
NORA VOLKOW, National Institute on Drug Abuse
STEVIN ZORN, Lundbeck Research
STEPHEN ZUKIN, AstraZeneca Pharmaceuticals
BRUCE M. ALTEVOGT, Project Director, Institute of Medicine
SARAH L. HANSON, Associate Program Officer (until June 2010)
SARA SHNIDER, Christine Mirzayan Science and Technology Policy Graduate Fellow (until May 2010)
LORA K. TAYLOR, Senior Project Assistant, Institute of Medicine
Institute of Medicine planning committees are solely responsible for organizing the workshop, identifying topics, and choosing speakers. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.
National Academies Press (US), Washington (DC)
Institute of Medicine (US) Forum on Neuroscience and Nervous System Disorders. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary. Washington (DC): National Academies Press (US); 2011. GLUTAMATE-RELATED BIOMARKERS IN DRUG DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM PLANNING COMMITTEE.